Search clinical trials for: Albumin-bound Paclitaxel plus S-1

Total 1145 results

Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Yuhong Li

Completed

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Cholangiocarcinoma

China
Sun Yat-sen University

Completed

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Gastric Cancer

China
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Terminated

First Line Chemotherapy for Advanced Cancer (GC-A-003)

Gastric Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer (CSAPPPCC)

Uterine Cervical Cancer

China
Affiliated Hospital of Qinghai University

Unknown

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Gastric Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Fudan University

Unknown

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Sai Life Sciences

Completed

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Solid Tumors

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NabucCO)

Metastatic Pancreatic Cancer

Italy
Sun Yat-sen University

Active, not recruiting

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Recurrent Cervical Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Huazhong University of Science and Technology
Chongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaborators

Recruiting

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical Cancer | Uterine Cervical Cancer | Uterine Cervical Neoplasm

China
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Yanqiao Zhang

Unknown

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

Pancreatic Cancer
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Ovarian Cancer
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan
M.D. Anderson Cancer Center

Active, not recruiting

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Taipei Veterans General Hospital, Taiwan

Completed

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Taiwan
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Cancer | HER2-positive Breast Cancer

China
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Muhammad Furqan
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Small Cell Lung Cancer (SCLC)

United States
Lei Li

Recruiting

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Chemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound Paclitaxel

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer (HNC-SYSU-005)

Oral Cancer

China
Junling Li

Unknown

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Extensive-Stage Small Cell Lung Cancer

China
Zhejiang University

Unknown

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer

Non Small Cell Lung Cancer

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
Taizhou EOC Pharma Co., Ltd.

Not yet recruiting

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Solid Tumor, Adult

Search clinical trials for: Albumin-bound Paclitaxel plus S-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations